MZE829
MZE829-201
Phase 2 small_molecule active
Quick answer
MZE829 for APOL1 Kidney Disease (AKD) is a Phase 2 program (small_molecule) at Maze Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Maze Therapeutics
- Indication
- APOL1 Kidney Disease (AKD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active